98%
921
2 minutes
20
Background: Immunohistochemistry (IHC) is a critical tool for tumor diagnosis and treatment, but it is time and tissue consuming, and highly dependent on skilled laboratory technicians. Recently, deep learning-based IHC biomarker prediction models have been widely developed, but few investigations have explored their clinical application effectiveness.
Methods: In this study, we aimed to create an automatic pipeline for the construction of deep learning models to generate AI-IHC (Artificial Intelligence) output using H&E whole slide images (WSIs) and compared the pathology reports by pathologists on AI-IHC versus conventional IHC. We obtained 134 WSIs including H&E and IHC pairs, and automatically extracted 415,463 tiles from H&E slides for model construction based on the annotation transfer from IHC slides. Five IHC biomarker prediction models (P40, Pan-CK, Desmin, P53, Ki-67) were developed to support a range of clinically relevant diagnostic applications across various gastrointestinal cancer subtypes, including esophageal, gastric, and colorectal cancers. The Ki-67 proliferation index was quantitatively assessed using digital image analysis.
Results: The AUCs of five IHC biomarker models ranged from 0.90 to 0.96 and the accuracies were between 83.04 and 90.81%. Additional 150 WSIs from 30 patients were collected to assess the effectiveness of AI-IHC through the multi-reader multi-case (MRMC) study. Each case was read by three pathologists, once on AI-IHC and once on conventional IHC with a minimum 2-week washout period. The results indicate that the consistency rates of pathologists in AI and conventional IHC cases were high in Desmin, Pan-CK and P40 (96.67-100%) while moderate in the P53 (70.00%). We also evaluated the T-stage through the staining of these IHC biomarkers and the consistency rate was 86.36%. Furthermore, the Ki-67 proliferation index, as reported by AI-IHC, showed a variability ranging from 17.35% ±16.2% compared to conventional IHC, with ICC of 0.415 (P = 0.015) between these two groups.
Conclusions: Here, we leveraged automatic tile-level annotations from H&E slides to efficiently develop deep learning-based IHC biomarker models, achieving AUCs between 0.90 and 0.96. AI generated IHC showed substantial concordance with conventional IHC across most markers, supporting its potential as an assistive tool in routine diagnostics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211442 | PMC |
http://dx.doi.org/10.1186/s12876-025-04045-0 | DOI Listing |
ESMO Open
September 2025
Department of Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Faculty of Medicine, University of Barcelona, Barcelona, Spain; Clínic Barcelona
Background: Response to trastuzumab combined with chemotherapy (T-chemo) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) varies widely, highlighting the need for more precise biomarkers beyond conventional HER2 assessment with immunohistochemistry (IHC) and in situ hybridization (ISH). The HER2DX ERBB2 messenger RNA (mRNA) assay, a clinically validated genomic test initially developed for early-stage HER2-positive breast cancer, quantitatively measures ERBB2 expression and may improve patient selection for T-chemo in AGC.
Patients And Methods: In a retrospective cohort of 134 patients with AGC, including 58 who received T-chemo, we evaluated whether the HER2DX ERBB2 score defines more accurately HER2 status and correlates with treatment response and survival outcomes in HER2-positive AGC, compared with standard pathology-based methods.
Small Methods
September 2025
Department of Pathology, College of Medicine, Hanyang University, Seoul, Republic of Korea.
While human epidermal growth factor receptor (HER2) has emerged as a tumor-agnostic biomarker, standard HER2 testing for anti-HER2 therapies using immunohistochemistry (IHC) and in situ hybridization (ISH) assays remains subjective, time-consuming, and often inaccurate. To address these limitations, an ultrafast and precise HER2 testing method is developed using Lab-On-An-Array (LOAA) digital real-time PCR (drPCR), a fully automated digital PCR enabling real-time absolute quantification. A multicenter study involving four independent breast cancer cohorts cross-validates the high diagnostic accuracy of drPCR-based HER2 assessment.
View Article and Find Full Text PDFFront Immunol
August 2025
Department of Pathology, Shenzhen Third People's Hospital (The Second Affiliated Hospital of Southern University of Science and Technology), Shenzhen, Guangdong, China.
Background: Pleomorphic giant cell adenocarcinoma (PGCA) of the prostate is a rare, aggressive variant characterized by multinucleated giant cells, sarcomatoid features, and resistance to conventional therapies. Despite its recognition in the WHO 2016 guidelines, the molecular drivers and clinicopathological correlates of PGCA remain poorly characterized. This study presents the first integrative clinicogenomic profiling of PGCA, revealing a novel prognostic gene signature with direct implications for diagnosis and treatment.
View Article and Find Full Text PDFIndian J Pathol Microbiol
August 2025
Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Introduction: Molecular subtyping of urothelial cancer of the bladder can help in identifying aggressive subtypes and aid in the prognostication of the disease. These subtypes can be broadly identified with the help of immunohistochemistry (IHC) markers reliably.
Aims: To assess the molecular subtypes of urothelial carcinoma of the bladder using IHC markers and evaluate their association with clinicopathological characteristics and overall survival (OS).
Clin Cosmet Investig Dent
August 2025
Ministry of Health, Qassim Health Cluster, King Saud Hospital, Unayzah, Kingdom of Saudi Arabia.
Background: Oral squamous cell carcinoma (OSCC) is a prevalent malignancy of the head and neck, often only diagnosed at advanced stages due to the limitations of conventional diagnostic tools. Early detection is crucial for improving survival rates, minimising treatment-related morbidity, and enhancing patient outcomes. Immunohistochemical (IHC) markers have emerged as potential tools for identifying early molecular changes associated with malignant transformation in oral epithelial cells.
View Article and Find Full Text PDF